🇺🇸 FDA
Patent

US 10558394

Injectable flowable composition comprising buprenorphine

granted A61KA61K31/00A61K31/4748

Quick answer

US patent 10558394 (Injectable flowable composition comprising buprenorphine) held by Indivior UK Limited expires Mon Feb 06 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Indivior UK Limited
Grant date
Tue Feb 11 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 06 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
28
CPC classes
A61K, A61K31/00, A61K31/4748, A61K31/485, A61K47/22